Abbisko says China NMPA clears ABSK211 pan-KRAS inhibitor for clinical trials

PUBT · 2d ago
Abbisko says China NMPA clears ABSK211 pan-KRAS inhibitor for clinical trials
  • Abbisko secured China NMPA clearance for an IND for ABSK211, an oral pan-KRAS inhibitor for KRAS-altered advanced solid tumors.
  • The program follows a July 8 FDA IND clearance, supporting a global clinical development plan.
  • An open-label Phase 1 study in China is set to start soon to assess safety, efficacy, and pharmacokinetics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12289757), on August 19, 2026, and is solely responsible for the information contained therein.